Drug Profile
BB 2827
Latest Information Update: 09 Apr 2009
Price :
$50
*
At a glance
- Originator British Biotech
- Developer British Biotech; Merck Serono
- Class Antirheumatics
- Mechanism of Action Matrix metalloproteinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Periodontal disorders; Rheumatoid arthritis
Most Recent Events
- 27 Jul 2001 Discontinued-I for Rheumatoid arthritis in Europe (PO)
- 26 Jun 2001 Investigation in Periodontal disorders in Europe (PO)
- 31 Oct 2000 Serono has an option to obtain exclusive rights to BB 2827